Advanced in Anaphylaxis

Yoichi Nakamura

Yokohama, JP 
Advanced in Anaphylaxis
Yokohama, JP 
OverviewLocationsClinical Research

Overview

Yoichi Nakamura practices in Yokohama, Japan. Mr. Nakamura is rated as an Advanced expert by MediFind in the treatment of Anaphylaxis. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Infantile Pyloric Stenosis, Gastrectomy, and Appendectomy.

His clinical research consists of co-authoring 91 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles in the study of Anaphylaxis.

Gender
Male

Locations

Yokohama, 2318682, Japan
Other Locations
Utsunomiya, Japan
Toyota, Japan
Tokyo, Japan
Tochigi, Japan
Ohashi, Japan
Nagasaki, 8528501, Japan
Izumisano, Japan
Hiroshima, 7348551, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Biological
Study Drug: Depemokimab
Study Phase: Phase 3
View 1 Less Clinical Trial

91 Total Publications

Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab.
Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Nakamura's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 24 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile